MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

12.65 -0.29 (-2.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
From Omeros Corporation
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2022 ↗
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Adagio Therapeutics (NASDAQ:ADGI) shares increased by 52.2% to $5.86 during Wednesday's pre-market session. The company's market cap stands at $651.9 million. 
Via Benzinga
News headline image
Omeros's Return On Capital Employed Insights ↗
According to Benzinga Pro, during Q4, Omeros (NASDAQ:OMER) earned $280.62 million, a 1336.05% increase from the preceding quarter. Omeros also posted a total of $30.84 million in... 
Via Benzinga
News headline image
Omeros: Q4 Earnings Insights ↗
Omeros (NASDAQ:OMER) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros missed... 
Via Benzinga
News headline image
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
From Omeros Corporation
Via Business Wire
News headline image
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a... 
Via Benzinga
News headline image
Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA ↗
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated... 
Via Benzinga
News headline image
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation (NASDAQ:OMER) Investor Notice: Investigation over Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Certain directors of Omeros Corporation are under investigation over potential breaches of fiduciary duties. 
Via SBWire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Applied DNA Sciences (NASDAQ:APDN... 
Via Benzinga
News headline image
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Lixte Biotech Holdings (NASDAQ:LIXT 
Via Benzinga
News headline image
Omeros Offloads Cataract Med Omidria To Rayner Surgical In Deal Valued Over $1B ↗
Omeros Corporation (NASDAQ: OMER) has agreed to sell Omidria to Rayner Surgical Group Limited for an upfront payment of $125 million with an additional $200... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Omeros (NASDAQ:OMER) stock increased by 15.68% to $7.89 during Thursday's pre-market session. The market value of their outstanding shares is at $493.4 million... 
Via Benzinga
News headline image
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
From Omeros Corporation
Via Business Wire
News headline image
76 Biggest Movers From Yesterday ↗
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares... 
Via Benzinga
Topics Initial Public Offering
News headline image
Omeros: Q3 Earnings Insights ↗
Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros... 
Via Benzinga
News headline image
Omeros Corporation Reports Third Quarter 2021 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
News headline image
Earnings Outlook For Omeros ↗
Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years ↗
Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA... 
Via Benzinga
News headline image
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
From Omeros Corporation
Via Business Wire
News headline image
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
From Omeros Corporation
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
News headline image
3 Beaten-Down Biotech Stocks -- Can They Recover? ↗
Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story